ANGPTL8: Target/Biomarker Introduction, products summarized (antibody/ADC/bispecific/antigen/ORF vector/VLP) and disease/indication/condition/MOA for drug discovery and IVD
It's the GeneMedi's summary page for Target/Biomarker Introduction of ANGPTL8. The page also collects GeneMedi's different modalities and formats products for ANGPTL8 in therapeutics/drug discovery and IVD diagnostics, which is including antibody, ADC, bispecific, antigen, ORF vector, VLP, etc. With GeneMedi's target-insight database-GM ITD database, the ANGPTL8 target is also connected to human indications/diseases/conditions/MOA.
Target sublocation: Secreted Protein/Potential Cytokines.
Predicted to enable hormone activity. Involved in regulation of lipid metabolic process and triglyceride homeostasis. Acts upstream of or within positive regulation of protein processing and regulation of lipoprotein metabolic process. Located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022]
| Target ID | GM-SE0614 |
| Target Name | ANGPTL8 |
| Gene ID | 55908,624219,100361444,106994638,102155149,102902262,101902412,111774288 |
| Gene Symbol and Synonyms | ANGPTL8,C19orf80,C7H19orf80,EG624219,Gm6484,PRO1185,PVPA599,RIFL,TD26 |
| Uniprot Accession | Q6UXH0 |
| Uniprot Entry Name | ANGL8_HUMAN |
| Protein Sub-location | Secreted Protein/Potential Cytokines |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000130173 |
| Target Classification | N/A |
Pre-made anti-ANGPTL8 inhibitory monoclonal antibody(mab, blocking antibody inhibitor)-benchmark antibody for drug discovery and mechanism of action (MOA) research
Pre-made anti-ANGPTL8 benchmark inhibitory monoclonal antibody(mab, blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic). The anti-ANGPTL8 mab is expressed and produced by mammalian cell line as a benchmark reference therapeutic antibody for biological drug discovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Antibody Name | Species | Format | Classified by tag | Detail |
| Anti-ANGPTL8 monoclonal antibody | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | mab | FACS/Biofunctional Antibody | Detail |
Recombinant multi-species ANGL8/ ANGPTL8/ C19orf80 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis
Genemedi produces Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine ANGPTL8 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
| Products Name | Species | Expression Platform | Detail |
| ANGPTL8 protein | Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine | Mammalian cell | Detail |
Pre-made ANGPTL8 viral vector in GM Promise-ORFTM
| Cat No. | Products name | NM ID | Species | Type | Detail |
| pGMLP004671 | human Angptl8 Lentivirus plasmid | NM_018687 | Human | Lentivirus plasmid | Detail |
| vGMLP004671 | human Angptl8 Lentivirus particle | NM_018687 | Human | Lentivirus particle | Detail |
About Promise-ORFTM:
Discover the largest collection of ORF/cDNA expression clones from different species, including human, mouse, rat, and more with GeneMedi's Promise-ORFTM. Our collection of ORFs expression clones come in verified mammalian or viral vectors lentivirus, AAV, and adenovirus) and our Promise-ORFTM viral-ready expression vectors make it easy for you to improve viral vector packaging efficiency or directly transfect mammalian cells, resulting in stronger and easier expression detection. Click to search your GOI
If you want to obtain higher quantities of plasmids (mg), please visit GM TransExcellent Plasmid DNA Rapid Preparation Service.